Literature DB >> 11745212

Lymphedema in a cohort of breast carcinoma survivors 20 years after diagnosis.

J A Petrek1, R T Senie, M Peters, P P Rosen.   

Abstract

BACKGROUND: To the authors' knowledge, there are no long-term cohort studies of lymphedema, despite the substantial morbidity of arm swelling. The goal of this study was to identify prevalence of breast carcinoma-related lymphedema, time of onset, and associated predictive factors.
METHODS: A cohort of 923 women consecutively treated with mastectomy and complete axillary dissection at our center between 1976 and 1978 was observed intensively for 20 years. Two hundred sixty-three study subjects (28.5%) who were alive and recurrence free constituted the cohort for the current study. A subset of 52 women (20% of study population) with contralateral mastectomy was analyzed separately. Subjects reported circumferential arm measurements taken using a validated instrument. In addition to providing analysis of clinical and treatment variables, this study is the first to the authors' knowledge to analyze possible etiologic factors in the posttreatment years, such as occupation, general physical activity, and sports/leisure activities. Univariate and multivariate analytic methods were used.
RESULTS: At 20 years after treatment, 49% (128 of 263) reported the sensation of lymphedema. Arm swelling measurements were severe (> or = 2.0 in [5.08 cm]; patients reported measurement in inches) for 13% (33 of 263 women). Seventy-seven percent (98 of 128) noted onset within 3 years after the operation; the remaining percentage developed arm swelling at a rate of almost 1% per year. Of the 15 potential predictive factors analyzed, only 2 were statistically significantly associated with lymphedema: arm infection/injury and weight gain since operation (P < 0.001 and P = 0.02, respectively).
CONCLUSIONS: This defined cohort, treated by axillary dissection 20 years ago, documents the high prevalence of lymphedema and its time course. Two significantly associated factors, both potentially controllable, are identified. The current study provides further support for treatments that limit lymph node dissection. The authors are prospectively evaluating patients undergoing sentinel lymph node biopsy. Copyright 2001 American Cancer Society.

Entities:  

Mesh:

Year:  2001        PMID: 11745212     DOI: 10.1002/1097-0142(20010915)92:6<1368::aid-cncr1459>3.0.co;2-9

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  145 in total

1.  Comparative morbidity of axillary lymph node dissection and the sentinel lymph node technique: implications for patients with breast cancer.

Authors:  Allan W Silberman; Carie McVay; Jason S Cohen; Jack F Altura; Sandra Brackert; Gregory P Sarna; Daphne Palmer; Albert Ko; Leslie Memsic
Journal:  Ann Surg       Date:  2004-07       Impact factor: 12.969

2.  Toll-like receptor deficiency worsens inflammation and lymphedema after lymphatic injury.

Authors:  Jamie C Zampell; Sonia Elhadad; Tomer Avraham; Evan Weitman; Seth Aschen; Alan Yan; Babak J Mehrara
Journal:  Am J Physiol Cell Physiol       Date:  2011-11-02       Impact factor: 4.249

3.  Possible genetic predisposition to lymphedema after breast cancer.

Authors:  Beth Newman; Felicity Lose; Mary-Anne Kedda; Mathias Francois; Kaltin Ferguson; Monika Janda; Patsy Yates; Amanda B Spurdle; Sandra C Hayes
Journal:  Lymphat Res Biol       Date:  2012-03-09       Impact factor: 2.589

4.  Use of sentinel lymph node biopsy to select patients for local-regional therapy after neoadjuvant chemotherapy.

Authors:  Lillian M Erdahl; Judy C Boughey
Journal:  Curr Breast Cancer Rep       Date:  2014-03

5.  Improving quality of life among latino cancer survivors: Design of a randomized trial of patient navigation.

Authors:  Amelie G Ramirez; Kipling J Gallion; Arely Perez; Edgar Munoz; Dorothy Long Parma; Patricia I Moreno; Frank J Penedo
Journal:  Contemp Clin Trials       Date:  2018-11-03       Impact factor: 2.226

6.  Regulation of inflammation and fibrosis by macrophages in lymphedema.

Authors:  Swapna Ghanta; Daniel A Cuzzone; Jeremy S Torrisi; Nicholas J Albano; Walter J Joseph; Ira L Savetsky; Jason C Gardenier; David Chang; Jamie C Zampell; Babak J Mehrara
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-02-27       Impact factor: 4.733

7.  Physical Activity and Lymphedema (the PAL trial): assessing the safety of progressive strength training in breast cancer survivors.

Authors:  Kathryn H Schmitz; Andrea B Troxel; Andrea Cheville; Lorita L Grant; Cathy J Bryan; Cynthia R Gross; Leslie A Lytle; Rehana L Ahmed
Journal:  Contemp Clin Trials       Date:  2009-01-08       Impact factor: 2.226

8.  Small Peptide Modulation of Fibroblast Growth Factor Receptor 3-Dependent Postnatal Lymphangiogenesis.

Authors:  David P Perrault; Gene K Lee; Sun Young Park; Sunju Lee; Dongwon Choi; Eunson Jung; Young Jin Seong; Eun Kyung Park; Cynthia Sung; Roy Yu; Antoun Bouz; Austin Pourmoussa; Soo Jung Kim; Young-Kwon Hong; Alex K Wong
Journal:  Lymphat Res Biol       Date:  2019-01-16       Impact factor: 2.589

9.  Treatment-related risk factors for arm lymphedema among long-term breast cancer survivors.

Authors:  Nandita Das; Richard N Baumgartner; Elizabeth C Riley; Christina M Pinkston; Dongyan Yang; Kathy B Baumgartner
Journal:  J Cancer Surviv       Date:  2015-04-26       Impact factor: 4.442

10.  Stretching exercises to reduce symptoms of postoperative neck discomfort after thyroid surgery: prospective randomized study.

Authors:  Yuuki Takamura; Akira Miyauchi; Chisato Tomoda; Takashi Uruno; Yasuhiro Ito; Akihiro Miya; Kaoru Kobayashi; Fumio Matsuzuka; Nobuyuki Amino; Kanji Kuma
Journal:  World J Surg       Date:  2005-06       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.